NATHAN FOWLER to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications NATHAN FOWLER has written about Antibodies, Monoclonal, Humanized.
Connection Strength
0.378
-
Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):356-364.e3.
Score: 0.072
-
Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides. Leuk Lymphoma. 2019 04; 60(4):1079-1082.
Score: 0.070
-
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study. J Clin Oncol. 2018 08 01; 36(22):2259-2266.
Score: 0.067
-
Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma. Curr Opin Oncol. 2015 Sep; 27(5):384-91.
Score: 0.056
-
Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. Ann Hematol. 2015 Apr; 94(4):633-41.
Score: 0.054
-
Safety and activity of pembrolizumab in combination with rituximab in relapsed or refractory follicular lymphoma. Blood Adv. 2022 02 22; 6(4):1143-1151.
Score: 0.022
-
RE-MIND: Comparing Tafasitamab + Lenalidomide (L-MIND) with a Real-world Lenalidomide Monotherapy Cohort in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Clin Cancer Res. 2021 11 15; 27(22):6124-6134.
Score: 0.021
-
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol. 2016 Aug; 17(8):1081-1093.
Score: 0.015